# Novavax clinical trials: 47 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials with Novavax as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Novavax: 47 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/novavax

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 25, 2025 | NCT07086222 | Efficacy and Safety of NVX-CoV2705 | Novavax | Phase 4 | Terminated | COVID-19, Sars-CoV-2 Infection | 6,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07086222) |
| October 9, 2024 | NCT06633835 | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | Novavax | Phase 4 | Completed | COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06633835) |
| July 3, 2024 | NCT06485752 | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | Novavax | Phase 2/3 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06485752) |
| July 1, 2024 | NCT06482359 | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | Novavax | Phase 2/3 | Withdrawn | COVID-19, Influenza | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482359) |
| May 10, 2024 | NCT06409663 | A Strain Change Study for SARS-CoV-2 rS Vaccines | Novavax | Phase 3 | Completed | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06409663) |
| March 4, 2024 | NCT06291857 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | Novavax | Phase 3 | Completed | COVID-19 | 9,320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06291857) |
| August 3, 2023 | NCT05975060 | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated... | Novavax | Phase 2/3 | Completed | COVID-19 | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05975060) |
| August 2, 2023 | NCT05973006 | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | Novavax | Phase 3 | Completed | COVID-19 | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05973006) |
| June 29, 2023 | NCT05925127 | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | Novavax | Phase 2/3 | Completed | COVID-19 | 994 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05925127) |
| May 25, 2023 | NCT05875701 | Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | Novavax | Phase 3 | Completed | COVID-19 | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05875701) |
| August 29, 2022 | NCT05519839 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine | Novavax | Phase 2 | Completed | COVID-19, Influenza | 1,579 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05519839) |
| July 21, 2022 | NCT05468736 | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to \< 12 Years | Novavax | Phase 2/3 | Completed | COVID-19 | 3,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05468736) |
| July 18, 2022 | NCT05463068 | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | Novavax | Phase 3 | Completed | COVID-19, SARS-CoV-2 Infection | 911 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05463068) |
| May 12, 2022 | NCT05372588 | Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | Novavax | Phase 3 | Completed | COVID-19, SARS CoV 2 Infection | 1,340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05372588) |
| November 9, 2021 | NCT05112848 | A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) | Novavax | Phase 2 | Completed | SARS-CoV-2 Infection | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05112848) |
| September 1, 2021 | NCT05029856 | Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults | Novavax | Phase 1/2 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05029856) |
| July 14, 2021 | NCT04961541 | Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine | Novavax | Phase 1/2 | Completed | SARS-CoV Infection, Covid19 | 637 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04961541) |
| November 2, 2020 | NCT04611802 | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in... | Novavax | Phase 3 | Completed | SARS-CoV Infection, Covid19 | 33,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04611802) |
| October 12, 2020 | NCT04583995 | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | Novavax | Phase 3 | Completed | SARS-CoV-2 Infection, COVID-19 | 15,185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04583995) |
| August 31, 2020 | NCT04533399 | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | Novavax | Phase 2 | Completed | SARS-CoV-2 Infection, COVID-19 | 4,422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04533399) |
| April 30, 2020 | NCT04368988 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | Novavax | Phase 1/2 | Completed | COVID-19 | 1,419 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04368988) |
| October 9, 2019 | NCT04120194 | Phase 3 Pivotal Trial of NanoFlu™ in Older Adults | Novavax | Phase 3 | Completed | Influenza, Human | 2,654 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04120194) |
| September 5, 2018 | NCT03658629 | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults | Novavax | Phase 2 | Terminated | Influenza, Human | 1,375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03658629) |
| September 26, 2017 | NCT03293498 | Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) | Novavax | Phase 1/2 | Completed | Influenza | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03293498) |
| January 20, 2017 | NCT03026348 | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™... | Novavax | Phase 2 | Completed | Respiratory Syncytial Viruses | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03026348) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 6 |
| Phase 2 | 16 |
| Phase 2/3 | 5 |
| Phase 3 | 11 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 42 |
| Withdrawn | 3 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 21 |
| Influenza, Human | 14 |
| Coronavirus Infections | 7 |
| Respiratory Syncytial Virus Infections | 4 |
| Severe Acute Respiratory Syndrome | 2 |
| Influenza in Birds | 1 |
| Hemorrhagic Fever, Ebola | 1 |
| Vaccine-Preventable Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B outdoor advertising companies in the United States](https://specstream.ai/data/businesses/b2b-outdoor-advertising-companies/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Inventory control companies in the United States](https://specstream.ai/data/businesses/inventory-control-companies/united-states)
- [Optometrists in the United States](https://specstream.ai/data/businesses/optometrists/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
